|Date||Analyst Firm||Analyst Name||Action||Rating||Action Price||Prior Price||Target|
You can purchase shares of TCR2 Therapeutics (NASDAQ: TCRR) through any online brokerage.
The latest price target for TCR2 Therapeutics (NASDAQ: TCRR) was reported by SVB Leerink on October 21, 2021. The analyst firm set a price target for 8.00 expecting TCRR to rise to within 12 months (a possible 16.96% upside). 9 analyst firms have reported ratings in the last year.
The stock price for TCR2 Therapeutics (NASDAQ: TCRR) is $6.84 last updated Mon Oct 25 2021 20:00:03 GMT+0000 (Coordinated Universal Time).
There are no upcoming dividends for TCR2 Therapeutics.
TCR2 Therapeutics’s $Q3 earnings are confirmed for after-market on $November 11, 2021.
There is no upcoming split for TCR2 Therapeutics.
TCR2 Therapeutics is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.